-
BeiGene’s Brukinsa Receives EC Approval for CLL Treatment
•
China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval from the European Committee (EC) for a new indication of its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib). The drug is now approved across the region to treat adult patients with treatment-naïve (TN) or relapsed/refractory…
-
Zhangjiang AI New Drug R&D Alliance Expands with New Members
•
The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche, Hengrui Pharmaceuticals, Wuxi Biologics, LianBio, Baidu, Ainnocence, Galixir, Nutshell Therapeutics, Infinite Intelligence Pharma, and more. This expansion marks a significant step in enhancing the collaborative research efforts within the alliance. Alliance OverviewThe joint effort, initiated…
-
Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging
•
Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised “tens of millions” of US dollars in a Series B financing round. The round was led by Eastern Bell Capital and Primavera Venture Partners, with contributions from Fusion Fund, 3E Bioventures, Banyan Pacific Capital, Delta…
-
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house developed drug candidates: HRS-1780, HRS-1358, and SHR-7367. These approvals mark significant milestones in the company’s pipeline development, positioning Hengrui to advance innovative treatments for chronic kidney disease and advanced malignant tumors. HRS-1780 ProfileHRS-1780 is an…
-
Rainsure Scientific Secures Series C1 Funding for Digital PCR Development
•
Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly raised “tens of millions” of renminbi in a Series C1 financing round led by Qiaodao Investment Fund. The proceeds will be used to further develop and commercialize the company’s innovative molecular diagnostics products. Company ProfileFounded…
-
CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for its recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA) has been accepted for review by the National Medical Products Administration (NMPA). The new indication filing is for the drug’s use as a thrombolytic therapy…
-
Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion
•
Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi in a Series A financing round. The round was led by IDG Capital and the People’s Insurance Company of China (PICC), with participation from GL Capital. The proceeds will be used for the late phase…
-
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858 obtained ethical approval at the First Affiliated Hospital of Guangzhou Medical University. The in-house developed Category 1 drug will be assessed for its efficacy and safety in a multi-center, randomized, double-blind, placebo-controlled Phase II study…
